Press release
Gossamer Bio Announces Early Encouraging Safety and Biomarker Data from Phase 1/2 Study of GB1275 at American Society of Clinical Oncology 2020 Virtual Scientific Program
SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and
About this update from Gossamer Bio, Inc.
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the presentation of positive safety and biomarker data at the 2020 American Society of Clinical Oncology Virtual Scientific Program (ASCO20) from its ongoing Phase 1/2 study of GB1275 in patients with selected solid tumors.\n\n\nThe KEYNOTE-A36 Phase 1/2 study is currently undergoing dose escalation of GB1275 as a monotherapy and in combination with KEYTRUDA® (pembrolizumab). As of the March 27, 2020 data cutoff, 22 patients had been enrolled in the study. GB1275 has been well tolerated to date, both as monotherapy and in combination with KEYTRUDA. No dose-limiting toxicities have been reported, and dose escalation in both arms continues. Dose-dependent increases in GB1275 plasma concentration have been observed, and the 7-hour elimination half-life of GB1275 supports BID, or twice-daily, dosing.\n\n\nConsistent with the proposed mechanism of GB1275, decreases in both peripheral monocytic and granulocytic myeloid-derived suppressor cells, or MDSCs, were observed following treatment with GB1275. Preliminary analyses also showed dose-dependent differences in peripheral gene expression profiles and unique transcriptomic expression patterns in patients treated with GB1275 monotherapy or combination with KEYTRUDA.\n\n\nEarly signs of activity were observed in a patient with metastatic castrate-resistant prostate cancer (mCRPC), who had previously experienced disease progression after more than ten lines of therapy, including treatment with atezolizumab, an anti-PDL1 antibody. The patient, enrolled in the lowest dosage cohort of the combination arm, experienced greater than 50% decreases in prostate-specific antigen (PSA) and neutrophil to lymphocyte ratio (NLR), both of which were sustained after four cycles of therapy. This patient was the only mCRPC patient enrolled at the time of data cutoff and remains on study treatment.\n\n\n“We are encouraged by the early signs of biologic and clinical activity observed as we have been able to safely dose escalate the GB1275 monotherapy and KEYTRUDA combination therapy regimens,” said Sheila Gujrathi, M.D., Co-Founder and Chief Exe...